Legend Biotech Corp
LEGN · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $8.77 — last insider sale, 2026-03-25 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D52gen composite 56pct→71; net + operating loss
Notable findings
- No interest coverageInterest coverage -6.38 (cannot cover interest)
- Cash burnNegative free cash flow (-128.8M)
- Net lossNet loss (net margin -28.8%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $902M cash & investments, ~28 quarters of runway
- Notable holderHeld by 5 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
61.4%
Operating margin
-13.3%
Net margin
-28.8%
Return on equity
-29.6%
Return on assets
-17.1%
ROIC
-8.2%
Revenue growth (QoQ)
64.2%
Debt / equity
0.3×
Interest coverage
-6.4×
Current ratio
2.0×
Free cash flow
-$129M
Tangible book value
$1.0B
Cash & investments
$902M
Cash runway
28q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Huang Ying | Chief Executive Officer | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-25 | Huang Ying | Sell | 9.9K | $8.77 |
All non-derivative Form 4 activity (SEC), newest first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-10 | 2025-12-31 | 0001801198-26-000008 ↗ |
| 20-F | 2025-03-11 | 2024-12-31 | 0001801198-25-000012 ↗ |
| 20-F | 2024-03-19 | 2023-12-31 | 0001801198-24-000021 ↗ |
| 20-F | 2023-03-30 | 2022-12-31 | 0001801198-23-000019 ↗ |
| 20-F | 2022-03-31 | 2021-12-31 | 0001564590-22-012769 ↗ |
| 20-F | 2021-04-02 | 2020-12-31 | 0001564590-21-017439 ↗ |